Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Adobe, Netflix, New York Times, Vical: U.S. Equity Movers

Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 4 p.m. in New York.

Adobe Systems Inc. (ADBE US) tumbled 19 percent to $26.67 for the biggest decline in the Standard & Poor’s 500 Index. The graphic-design software maker forecast sales that trailed estimates, citing slower demand from back-to-school shoppers and Japanese buyers.

Autodesk Inc. (ADSK US), whose software is used in bridge design and movie special effects, fell 4.3 percent to $31.66.

AMR Corp. (AMR US) slid 8.7 percent, the most since April 21, to $6.28. The owner of American Airlines said its mainline unit revenue will increase 11 percent at most in the third quarter. That trailed Deutsche Bank AG’s estimate for a gain of 12 percent. JPMorgan Chase & Co. and Stifel Nicolaus & Co. both widened their 2010 loss estimates for the airline.

Analogic Corp. (ALOG US) rose 3.2 percent, the most since Aug. 25, to $44.31. The medical and airport-security device maker reported fourth-quarter earnings of 56 cents a share, beating the average analyst estimate of 39 cents a share.

Biogen Idec Inc. (BIIB US) declined 5.8 percent, the most since Oct. 23, to $54.86. The world’s largest maker of multiple-sclerosis treatments fell after Novartis AG’s MS drug Gilenya won U.S. regulatory approval.

CarMax Inc. (KMX US) rose the most in the S&P 500, jumping 8.5 percent to $26.16. The biggest U.S. used-car dealer reported second-quarter per-share earnings of 48 cents, beating analysts’ average estimate of 40 cents a share. The company, which had a 13 percent increase in second-quarter revenue, said it plans to open five superstores in 2012.

Catalyst Health Solutions Inc. (CHSI US) slumped 12 percent, the most since December 2008, to $32.69. The provider of pharmacy benefit management services said it’s involved in a contractual dispute with its client MCS Advantage Inc., which threatens to terminate the agreement at the end of the year.

Force Protection Inc. (FRPT US) climbed 13 percent to $4.76 for the biggest gain in Russell 2000 Index. The maker of blast-resistant trucks for the U.S. military said its European unit was picked by the U.K. government as the preferred bidder in Light Protected Patrol Vehicle program.

General Mills Inc. (GIS US) rose 2.7 percent, the most since June 2, to $36.63. The maker of Cheerios and Green Giant frozen vegetables said first-quarter profit gained 12 percent, helped by rising sales of cereals and snacks. Profit excluding some items was 64 cents a share, beating analysts’ estimates by 1 cent.

IStar Financial Inc. (SFI US) had the second-biggest retreat in Russell 2000 Index, losing 15 percent to $2.95. The commercial real estate lender fell for a second day after people with knowledge of the plan said the company trying to restructure some of its $8.6 billion of debt may seek bankruptcy protection.

Jefferies Group Inc. (JEF US) slid 5.2 percent, the most July 16, to $23. The first Wall Street firm to release third-quarter results reported earnings that missed analysts’ estimates as trading revenue declined.

Microsoft Corp. (MSFT US) fell the most in the Dow Jones Industrial Average, losing 2.2 percent to $24.61. The world’s biggest software maker raised quarterly dividend by 23 percent to 16 cents a share. The magnitude was “disappointing,” according to Cowen & Co. analyst Gregg Moskowitz, who said the 2.5 percent yield fell short of his expectation of as much as 4 percent.

Netflix Inc. (NFLX US) rose 6.6 percent to a record $156.93. The mail-order and online movie-rental service gained after the Wall Street Journal reported that a bankruptcy filing by rival Blockbuster Inc. may come in the next few days.

New York Times Co. (NYT US) fell 6.5 percent, the most since July 28, to $7.45. The newspaper publisher predicted third-quarter sales that trailed analysts’ estimates as circulation revenue drops.

Gannett Co. (GCI US), the owner of USA Today and television stations, dropped 6.2 percent to $12.36.

OncoGenex Pharmaceuticals Inc. (OGXI US) rose 6.3 percent, the most since July 27, to $13.01. The Bothell, Washington-based drugmaker said its custirsen treatment helped improve survival rates in patients with advanced prostate cancer.

PMC-Sierra Inc. (PMCS US) sank 6 percent to $7.32 for the biggest decline since Aug. 11. The chipmaker reduced its third-quarter sales forecast, saying it expects $163 million at most. That trails the average analyst estimate of $173.5 million in a Bloomberg survey.

Power-One Inc. (PWER US) gained 6.1 percent to $9.24, after dropping to a three-month low last week. The maker of power-conversion products for communications equipment said it plans to buy back 10 million shares.

Satyam Computer Services Ltd. (SAY US) surged 20 percent, the most since August 2009, to $6.61. The Indian software exporter, which delayed reporting its accounts after disclosing an overstatement of assets, said it will report annual earnings this month, its first since the company was embroiled in India’s biggest corporate fraud probe.

Theravance Inc. (THRX US) rose 6.1 percent to $18.23, the highest price since September 2009. GlaxoSmithKline Plc (GSK LN) and Theravance said a study showed their experimental Relovair drug was safe and improved lung function in patients with chronic obstructive pulmonary disorder.

Vical Inc. (VICL US) plunged 32 percent to $2.62 for the biggest loss in Russell 2000 Index. Sanofi-Aventis SA (SAN FP) said a drug developed by Vical that had showed promise in restoring blood vessel growth in damaged limbs was no better than a placebo in an advanced test.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.